Agree, RYN, we could get a bucketload of cash that would provide...

Agree, RYN, we could get a bucketload of cash that would provide finance for many of the prospects that ANP has mentioned this year.

At recent conferences they've quoted:

"Look beyond DMD - there's much greater opportunity to add value elsewhere" .....so ? MS?
" We are re-engaging with pharmaceutical companies active in the MS space to discuss partnering opportunities" - "shareholders should be very excited"


Interview with Tim Boreham 12/2/20 re Acromeglia, "we are talking to potential partners"
14/4/20 re Acro "in partnering discussions now"

And we see in the graph below ANP's estimated timing for ATL 1103 Partnering - before our DMD trial application that has been touted before the end of this year....so another potential source of cash from some upfronts in the next three months?

So in addition to private and government grants and potential to use the 15% of shareholders' equity cap raise, there are other sources of significant funding for the much discussed MS and Acro as well as a few other conditions alluded to.

As our friend says - we should be excited.